Nuvation Bio announced $18.5 million in net product revenue for IBTROZI (taletrectinib) in Q1 2026, with strong adoption among newly treated patients with advanced ROS1-positive NSCLC. The company also acquired global development and commercialization rights to safusidenib, an investigational drug for IDH1-mutant glioma, expanding its oncology portfolio. Updated clinical data showed IBTROZI's durable response and progression-free survival, supporting its growing role as a standard treatment. Nuvation Bio maintains a strong cash position of $533.7 million and plans further updates on its drug conjugate platform later in 2026.
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
The global consumer finance market is projected to expand from $9.87 trillion in 2025 to $14.08 trillion by 2031, growing at a 6.17% CAGR. Key growth drivers include embedded finance at point-of-sale, which boosts credit uptake by integrating lending...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
